Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS WERE $68.3 MILLION, COMPARED TO $59.8 MILLION AS OF DECEMBER 31, 2018.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS BEYOND EXPECTED NDA SUBMISSION.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO Q1 OF 2021.
Full Article
May 6 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FOR ZYGEL™ FOR THE TREATMENT OF BEHAVIORAL SYMPTOMS ASSOCIATED WITH FRAGILE X SYNDROME (FXS).ZYNERBA PHARMACEUTICALS - ENROLLMENT PROGRESSING IN PIVOTAL CONNECT-FX TRIAL OF ZYGEL IN FXS, WITH DATA EXPECTED IN SECOND HALF OF 2019.
Full Article
March 14 (Reuters) - SCYNEXIS Inc ::SCYNEXIS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.SCYNEXIS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $44.2 MILLION AS OF DECEMBER 31, 2018.SCYNEXIS INC - NET LOSS FOR 2018 WAS $12.5 MILLION, OR $0.28 PER SHARE.
Full Article
Jan 4 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS INC - WELL CAPITALIZED WITH CASH RUNWAY EXPECTED INTO SECOND HALF OF 2020 - SEC FILING.ZYNERBA PHARMACEUTICALS - DELAYING PHASE 2B OF ZYN002 IN ADULT REFRACTORY FOCAL EPILEPSY UNTIL AFTER READOUT OF FOUR CHILDHOOD NEUROPSYCH STUDIES.
Full Article
Dec 17 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES CLINICAL UPDATE AND ANNOUNCES TWO NEW CLINICAL INDICATIONS.ZYNERBA PHARMACEUTICALS INC - CASH RUNWAY NOW EXTENDS INTO SECOND HALF OF 2020.ZYNERBA - COMPANY WILL FOCUS ON FOUR CHILDHOOD NEUROPSYCHIATRIC DISORDERS: FXS, DEE, AUTISM SPECTRUM DISORDER AND 22Q11.2 DELETION SYNDROME.ZYNERBA PHARMACEUTICALS - POSTPONED INITIATION OF CLINICAL TRIAL IN ADULT EPILEPSY UNTIL AFTER COMPLETION OF FOUR CHILDHOOD NEUROPSYCHIATRIC STUDIES.ZYNERBA PHARMACEUTICALS INC - FRAGILE X SYNDROME PIVOTAL DATA EXPECTED IN 2H2019.ZYNERBA PHARMACEUTICALS - REMAINS ON TRACK TO REPORT TOP LINE RESULTS FROM CONNECT-FX (CLINICAL STUDY OF CANNABIDIOL (CBD) IN CHILDREN IN H2 2019.ZYNERBA - ADDITION OF NEW CHILDHOOD NEUROPSYCHIATRIC CLINICAL TARGETS FOR ZYN002; AUTISM SPECTRUM DISORDER & 22Q11.2 DELETION SYNDROME.ZYNERBA - EXPECTS TO INITIATE OPEN LABEL PHASE 2 STUDIES IN HI 2019, REPORT TOP-LINE RESULTS IN H1 2020 FOR NEW CLINICAL INDICATIONS.
Full Article
Nov 8 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q3 LOSS PER SHARE $0.47.Q3 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.
Full Article
May 8 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.ZYNERBA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.91.ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $52.1 MILLION AS OF MARCH 31, IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO 2019.
Full Article
March 12 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q4 LOSS PER SHARE $0.60.Q4 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS - BELIEVES CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019.
Full Article
March 5 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING.ZYNERBA - EXPECTS TO INITIATE SINGLE PIVOTAL STUDY MID-YEAR 2018 TO SUPPORT NDA FOR ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS SAYS FDA & CO ARE IN AGREEMENT OVER PRIMARY & KEY SECONDARY ENDPOINTS FOR ZYN002 IN FRAGILE X SYNDROME.
Full Article
Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE.ZYNERBA PHARMACEUTICALS INC - PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018.ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS.ZYNERBA - IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES.ZYNERBA PHARMACEUTICALS INC - PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019.
Full Article
Earnings vs. 
Estimates